# Clinical Trials Data BRAF - Document 37

# Expanded Access Program With Nivolumab to Treat Melanoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT02142218

"eligibilityCriteria": "For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n\* ECOG Performance Status of 0-1\n\* Histologically confirmed malignant melanoma\n\* Progressed on or after treatment with an anti-CTLA4\n\nExclusion Criteria:\n\n\* Active brain metastases\n\* Life Expectancy \\<6 weeks\n\* Subjects who received prior therapy targeting T-cell costimulation or checkpoint pathways except for Anti CTLA-4 therapy\n\* Subjects with autoimmune disease",  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
This trial information \*\*does not mention BRAF mutation status\*\* as either an inclusion or exclusion criterion. Therefore, based on the information provided, it's \*\*impossible to determine\*\* if a patient with a BRAF mutation would be eligible. They would need to check the detailed information at www.BMSStudyConnect.com or contact the study organizers. The presence or absence of a BRAF mutation might be an important factor for this type of trial (melanoma), so further investigation is essential.